| Name | Title | Contact Details |
|---|---|---|
Christian Daniels |
Director of Finance | Profile |
Denton County MHMR Center mission is to enhance the quality of life of the individuals served and their family members. Crisis Line 24/7: 1-800-762-0157
La Jolla Pharmaceutical Company is a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases. The Company has four product candidates in development. LJPC-501 is La Jolla’s proprietary formulation of angiotensin II for the potential treatment of catecholamine-resistant hypotension and hepatorenal syndrome. GCS-100 is La Jolla’s first-in-class galectin-3 inhibitor for the potential treatment of chronic kidney disease. LJPC-1010, La Jolla’s second-generation galectin-3 inhibitor, is a more potent and purified derivative of GCS-100 that can be delivered orally for the potential treatment of nonalcoholic steatohepatitis and other diseases characterized by tissue fibrosis. LJPC-401 is La Jolla’s novel formulation of hepcidin for the potential treatment of conditions characterized by iron overload, such as hemochromatosis and beta thalassemia
With over 25 years of experience, MEDISCA has developed a solid reputation as an innovative and entrepreneurial company in the pharmaceutical compounding industry.
Cincinnati-based surgical procedure company focused on innovative development, commercialization of medical devices for treatment of obesity, gastrectomy.